ASX:PNV

Bell Potter Upgrades PolyNovo to Buy from Hold; Price Target is AU$1.22

PolyNovo (ASX:PNV) has an average rating of overweight and mean price target of AU$1.28, according to analysts polled by FactSet.

PolyNovo Fiscal 2026 Earnings Down, Revenue Up

PolyNovo (ASX:PNV) logged AU$0.0105 in earnings per share for fiscal 2026, compared with AU$0.0189 a year ago, a Wednesday filing showed.For the 12 months ended June 30, total revenue was AU$150 million versus AU$129.2 million previously, the Australia-listed medical technology company added.

Bell Potter Downgrades PolyNovo to Hold from Buy; Price Target is AU$1

PolyNovo Reports Higher Fiscal 2026 Group Revenue

PolyNovo (ASX:PNV) reported preliminary fiscal 2026 revenue of AU$150 million, up over 16% from AU$129.2 million in the prior corresponding period, according to a Thursday Australian bourse filing.Group commercial sales increased nearly 17% to AU$138.4 million from AU$118.6 million, while US commercial sales grew about 16% to AU$102.1 million, up from AU$88.4 million in the prior period.Rest of world commercial sales increased 20% to AU$36.3 million, compared with AU$30.3 million in the prior period, the filing said.Cash and cash equivalents as of June 30 was AU$35.4 million, the filing added.The company will release its fiscal 2026 financial report on Aug. 26.

PolyNovo Says JPMorgan Chase Ceases to Be Substantial Holder

PolyNovo (ASX:PNV) said JPMorgan Chase and its affiliates ceased to be substantial holders of the firm on June 19, according to a Wednesday Australian bourse filing.JPMorgan Chase Bank, N.A. placed 389,426 ordinary shares of the firm as a loan to Bofa Securities as an agent lender.

PolyNovo Says US PMA Submission for NovoSorb BTM Now Expected Before 2026-End; Shares Down 4%

PolyNovo (ASX:PNV) said the clinical study report for its US pivotal randomized controlled trial of NovoSorb BTM has been finalized, with the premarket approval (PMA) submission now expected before the end of calendar 2026, according to a Friday Australian bourse filing.NovoSorb, the company's polymer, is made to address unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the company is leveraging the technology platform to develop new products and markets, the filing said.The company said it has proactively refined its PMA submission plan following updated Food and Drug Administration (FDA) guidance effective from February, including the sequencing of key manufacturing and validation activities, with certain activities originally planned post-submission to be included to strengthen the submission package.The revised timing does not impact current sales or clinical use of NovoSorb products, the filing added.The company's shares fell 4% in recent Friday trade.

PolyNovo Says JPMorgan Chase Reduces Stake; Shares Up 5%

PolyNovo (ASX:PNV) received notice that JPMorgan Chase and its affiliates decreased their holdings in the company to 7.45% from 9.18%, according to a Monday Australian bourse filing.JPMorgan Chase and its affiliates now own 51.5 million shares in the company, the filing said.The company's shares rose 5% in recent Monday trade.

PolyNovo Says JPMorgan Chase's Voting Power Rises to 9.18%, Shares Fall 3%

PolyNovo (ASX:PNV) said that the voting power of JPMorgan Chase and its affiliates in the firm increased to 9.18% from 7.89%, as of Tuesday, according to an Australian bourse filing on Friday.JPMorgan Chase and its affiliates now hold 63.4 million shares in the firm.Its shares fell 3% in recent trading on Friday.

PolyNovo Appoints Chief Scientific Officer

PolyNovo (ASX:PNV) appointed Marthe D'Ombrain as chief scientific officer, effective June 1, according to a Wednesday filing with the Australian bourse.D'Ombrain most recently served as executive director and head of global research innovation at CSL (ASX:CSL), the filing added.